Top

28-04-2024

Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study

Authors: Mina S. Sedrak, Can-Lan Sun, Marie Bae, Rachel A. Freedman, Allison Magnuson, Tracey O’Connor, Beverly Moy, Tanya M. Wildes, Heidi D. Klepin, Andrew E. Chapman, William P. Tew, Efrat Dotan, Mary Anne Fenton, Heeyoung Kim, Vani Katheria, Hyman B. Muss, Harvey J. Cohen, Cary P. Gross, Jingran Ji

Published in: Journal of Cancer Survivorship

Abstract

Purpose

This study aimed to assess whether physical functional decline in older women with early-stage breast cancer is driven by cancer, chemotherapy, or a combination of both.

Methods

We prospectively sampled three groups of women aged ≥ 65: 444 with early-stage breast cancer receiving chemotherapy (BC Chemo), 98 with early-stage breast cancer not receiving chemotherapy (BC Control), and 100 non-cancer controls (NC Control). Physical function was assessed at two timepoints (T1 [baseline] and T2 [3, 4, or 6 months]) using the Physical Functioning Subscale (PF-10) of the RAND 36-item Short Form. The primary endpoint was the change in PF-10 scores from T1 to T2, analyzed continuously and dichotomously (Yes/No, with "yes" indicating a PF-10 decline > 10 points, i.e., a substantial and clinically meaningful difference).

Results

Baseline PF-10 scores were similar across all groups. The BC Chemo group experienced a significant decline at T2, with a median change in PF-10 of -5 (interquartile range [IQR], -20, 0), while BC Control and NC Control groups showed a median change of 0 (IQR, -5, 5; p < 0.001). Over 30% of BC Chemo participants had a substantial decline in PF-10 vs. 8% in the BC Control and 5% in the NC Control groups (p < 0.001).

Conclusion

In this cohort of older adults with early-stage breast cancer, the combination of breast cancer and chemotherapy contributes to accelerated functional decline. Our findings reinforce the need to develop interventions aimed at preserving physical function, particularly during and after chemotherapy.

Implications for Cancer Survivors

The high prevalence of accelerated functional decline in older women undergoing breast cancer chemotherapy underscores the urgency to develop interventions aimed at preserving physical function and improving health outcomes.

Clinical Trial

NCT01472094, Hurria Older PatiEnts (HOPE) with Breast Cancer Study.

Available only for authorised users

Petrick JL, Reeve BB, Kucharska-Newton AM, Foraker RE, Platz EA, Stearns SC, et al. Functional status declines among cancer survivors: Trajectory and contributing factors. J Geriatric Oncol. 2014;5:359–67. https://doi.org/10.1016/j.jgo.2014.06.002.CrossRef

Winters-Stone KM, Medysky ME, Savin MA. Patient-reported and objectively measured physical function in older breast cancer survivors and cancer-free controls. J Geriatric Oncol. 2019;10:311–6. https://doi.org/10.1016/j.jgo.2018.10.006.CrossRef

Bennett JA, Winters-Stone KM, Dobek J, Nail LM. Frailty in Older Breast Cancer Survivors: Age, Prevalence, and Associated Factors. Oncol Nurs Forum. 2013;40:E126–34. https://doi.org/10.1188/13.ONF.E126-E134.CrossRefPubMedPubMedCentral

Karlsen RV, Frederiksen K, Larsen MB, von Heymann-Horan AB, Appel CW, Christensen J, et al. The impact of a breast cancer diagnosis on health-related quality of life. A prospective comparison among middle-aged to elderly women with and without breast cancer. Acta Oncologica. 2016;55:720–7. https://doi.org/10.3109/0284186X.2015.1127415.CrossRefPubMed

Weaver KE, Leach CR, Leng X, Danhauer SC, Klepin HD, Vaughan L, et al. Physical Functioning among Women 80 Years of Age and Older With and Without a Cancer History. GERONA. 2016;71:S23-30. https://doi.org/10.1093/gerona/glv073.CrossRef

Sedrak MS, Kirkland JL, Tchkonia T, Kuchel GA. Accelerated aging in older cancer survivors. J Am Geriatr Soc. 2021;69:3077–80. https://doi.org/10.1111/jgs.17461.CrossRefPubMedPubMedCentral

Amitani M, Oba T, Kiyosawa N, Morikawa H, Chino T, Soma A, et al. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer. BMC Cancer. 2022;22:327. https://doi.org/10.1186/s12885-022-09443-1.CrossRefPubMedPubMedCentral

Guigni BA, Callahan DM, Tourville TW, Miller MS, Fiske B, Voigt T, et al. Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am J Physiol Cell Physiol. 2018;315:C744–56. https://doi.org/10.1152/ajpcell.00002.2018.CrossRefPubMedPubMedCentral

Mandelblatt JS, Zhou X, Small BJ, Ahn J, Zhai W, Ahles T, et al. Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study. JNCI: J National Cancer Inst. 2021;113:1053–64. https://doi.org/10.1093/jnci/djab003.CrossRef

10.

Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR. Physical and Psychosocial Recovery in the Year After Primary Treatment of Breast Cancer. JCO. 2011;29:1101–9. https://doi.org/10.1200/JCO.2010.28.8043.CrossRef

11.

Deimling GT, Arendt JA, Kypriotakis G, Bowman KF. Functioning of Older, Long-Term Cancer Survivors: The Role of Cancer and Comorbidities: CANCER AND COMORBIDITIES. J Am Geriatr Soc. 2009;57:S289–92. https://doi.org/10.1111/j.1532-5415.2009.02515.x.CrossRefPubMed

12.

Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061–6. https://doi.org/10.1056/NEJMsa012528.CrossRefPubMed

13.

Seghers PALN, Wiersma A, Festen S, Stegmann ME, Soubeyran P, Rostoft S, et al. Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient-A Systematic Review. Cancers (Basel). 2022;14:1147. https://doi.org/10.3390/cancers14051147.CrossRefPubMed

14.

Fried TR, Tinetti ME, Iannone L, O’Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med. 2011;171:1854–6. https://doi.org/10.1001/archinternmed.2011.424.CrossRefPubMedPubMedCentral

15.

DuMontier C, Loh KP, Soto-Perez-de-Celis E, Dale W. Decision Making in Older Adults With Cancer. J Clin Oncol. 2021;39:2164–74. https://doi.org/10.1200/JCO.21.00165.CrossRefPubMedPubMedCentral

16.

Nightingale G, Battisti NML, Loh KP, Puts M, Kenis C, Goldberg A, et al. Perspectives on functional status in older adults with cancer: An interprofessional report from the International Society of Geriatric Oncology (SIOG) nursing and allied health interest group and young SIOG. J Geriatr Oncol. 2021;12:658–65. https://doi.org/10.1016/j.jgo.2020.10.018.CrossRefPubMed

17.

Office of Cancer Survivorship. Statistics, Graphs and Definitions. Statistics, Graphs and Definitions n.d. https://cancercontrol.cancer.gov/ocs/statistics (accessed August 23, 2021).

18.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA CANCER J CLIN. 2019;69:24.CrossRef

19.

Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, et al. Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors. J Natl Cancer Inst. 2019;111:1245–54. https://doi.org/10.1093/jnci/djz136.CrossRefPubMedPubMedCentral

20.

Guida JL, Agurs-Collins T, Ahles TA, Campisi J, Dale W, Demark-Wahnefried W, et al. Strategies to Prevent or Remediate Cancer and Treatment-Related Aging. JNCI: J Nat Cancer Inst. 2021;113:112–22. https://doi.org/10.1093/jnci/djaa060.CrossRefPubMed

21.

Gresham G, Dy SM, Zipunnikov V, Browner IS, Studenski SA, Simonsick EM, et al. Fatigability and endurance performance in cancer survivors: Analyses from the Baltimore Longitudinal Study of Aging: Fatigability in Cancer Survivors. Cancer. 2018;124:1279–87. https://doi.org/10.1002/cncr.31238.CrossRefPubMed

22.

Cespedes Feliciano EM, Vasan S, Luo J, Binder AM, Chlebowski RT, Quesenberry C, et al. Long-term Trajectories of Physical Function Decline in Women With and Without Cancer. JAMA Oncol. 2023;9:395–403. https://doi.org/10.1001/jamaoncol.2022.6881.CrossRefPubMedPubMedCentral

23.

Siddique A, Simonsick EM, Gallicchio L. Functional decline among older cancer survivors in the Baltimore longitudinal study of aging. J Am Geriatr Soc. 2021:jgs.17369. https://doi.org/10.1111/jgs.17369.

24.

Michael YL, Wu C, Pan K, Seguin-Fowler RA, Garcia DO, Zaslavsky O, et al. Postmenopausal Breast Cancer and Physical Function Change: A Difference-in-Differences Analysis. J Am Geriatr Soc. 2020;68:1029–36. https://doi.org/10.1111/jgs.16323.CrossRefPubMed

25.

Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, et al. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019;67:920–7. https://doi.org/10.1111/jgs.15493.CrossRefPubMed

26.

Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM, et al. Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging? JCO. 2017;35:149–56. https://doi.org/10.1200/JCO.2016.67.1883.CrossRef

27.

Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, et al. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. JCO. 2021;39:608–18. https://doi.org/10.1200/JCO.20.02063.CrossRef

28.

Ji J, Sun C-L, Cohen HJ, Muss HB, Bae M, Sedrak MS. Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors. J Natl Cancer Inst. 2023;115:578–85. https://doi.org/10.1093/jnci/djad029.CrossRefPubMedPubMedCentral

29.

Ji J, Sun C-L, Cohen HJ, Synold T, Muss H, Sedrak MS. Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study. J Clin Oncol. 2023;41:307–15. https://doi.org/10.1200/JCO.22.01217.CrossRefPubMed

30.

Sedrak MS, Sun C-L, Ji J, Cohen HJ, Gross CP, Tew WP, et al. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. J Clin Oncol. 2023;41:316–26. https://doi.org/10.1200/JCO.22.01440.CrossRefPubMed

31.

Okabe T, Suzuki M, Goto H, Iso N, Cho K, Hirata K, et al. Sex Differences in Age-Related Physical Changes among Community-Dwelling Adults. J Clin Med. 2021;10:4800. https://doi.org/10.3390/jcm10204800.CrossRefPubMedPubMedCentral

32.

Lin M-H, Chen L-J, Huang S-T, Meng L-C, Lee W-J, Peng L-N, et al. Age and sex differences in associations between self-reported health, physical function, mental function and mortality. Arch Gerontol Geriatr. 2022;98: 104537. https://doi.org/10.1016/j.archger.2021.104537.CrossRefPubMed

33.

Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: A feasibility study. Cancer. 2005;104:1998–2005. https://doi.org/10.1002/cncr.21422.CrossRefPubMed

34.

Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65. https://doi.org/10.1200/JCO.2011.34.7625.CrossRefPubMedPubMedCentral

35.

Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. J Clin Oncol. 2016;34:2366–71. https://doi.org/10.1200/JCO.2015.65.4327.CrossRefPubMedPubMedCentral

36.

Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220–4. https://doi.org/10.1002/1097-0142(19800415)45:8%3c2220::aid-cncr2820450835%3e3.0.co;2-q.CrossRefPubMed

37.

Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8. https://doi.org/10.1111/j.1532-5415.1991.tb01616.x.CrossRefPubMed

38.

Kawas C, Karagiozis H, Resau L, Corrada M, Brookmeyer R. Reliability of the Blessed Telephone Information-Memory-Concentration Test. J Geriatr Psychiatry Neurol. 1995;8:238–42. https://doi.org/10.1177/089198879500800408.CrossRefPubMed

39.

Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36:428–34. https://doi.org/10.1093/geronj/36.4.428.CrossRefPubMed

40.

Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92. https://doi.org/10.1001/jama.285.7.885.CrossRefPubMed

41.

Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10. https://doi.org/10.7326/0003-4819-120-2-199401150-00002.CrossRefPubMed

42.

Stewart AL, Ware JE, editors. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University Press; 1992.

43.

Veit CT, Ware JE. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol. 1983;51:730–42. https://doi.org/10.1037//0022-006x.51.5.730.CrossRefPubMed

44.

McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care. 1992;30:MS253-265. https://doi.org/10.1097/00005650-199205001-00025.CrossRefPubMed

45.

Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705–14. https://doi.org/10.1016/0277-9536(91)90150-b.CrossRefPubMed

46.

Antonescu I, Carli F, Mayo NE, Feldman LS. Validation of the SF-36 as a measure of postoperative recovery after colorectal surgery. Surg Endosc. 2014;28:3168–78. https://doi.org/10.1007/s00464-014-3577-8.CrossRefPubMed

47.

Bohannon RW, DePasquale L. Physical Functioning Scale of the Short-Form (SF) 36: internal consistency and validity with older adults. J Geriatr Phys Ther. 2010;33:16–8.PubMed

48.

Almutairi KM, Alodhayani AA, Alonazi WB, Vinluan JM. Assessment of Health-Related Quality of Life Among Caregivers of Patients with Cancer Diagnosis: A Cross-Sectional Study in Saudi Arabia. J Relig Health. 2017;56:226–37. https://doi.org/10.1007/s10943-016-0261-4.CrossRefPubMed

49.

Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002;94:39–49. https://doi.org/10.1093/jnci/94.1.39.CrossRefPubMed

50.

Kokkonen K, Saarto T, Mäkinen T, Pohjola L, Kautio H, Järvenpää S, et al. The functional capacity and quality of life of women with advanced breast cancer. Breast Cancer. 2017;24:128–36. https://doi.org/10.1007/s12282-016-0687-2.CrossRefPubMed

51.

Pruitt SL, McQueen A, Deshpande AD, Jeffe DB, Schootman M. Mediators of the effect of neighborhood poverty on physical functioning among breast cancer survivors: a longitudinal study. Cancer Causes Control. 2012;23:1529–40. https://doi.org/10.1007/s10552-012-0030-y.CrossRefPubMedPubMedCentral

52.

Teo BJX, Koh JSB, Jiang L, Allen JC, Yeo SJ, Howe TS. Association of the 36-Item Short Form Health Survey Physical Component Summary Score With Patient Satisfaction and Improvement 2 Years After Total Knee Arthroplasty. JAMA Netw Open. 2019;2: e190062. https://doi.org/10.1001/jamanetworkopen.2019.0062.CrossRefPubMedPubMedCentral

53.

Escobar A, Quintana JM, Bilbao A, Aróstegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthritis Cartilage. 2007;15:273–80. https://doi.org/10.1016/j.joca.2006.09.001.CrossRefPubMed

54.

Pan K, Ray RM, Cauley JA, Shadyab AH, Hurria A, Chlebowski RT. Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls. Breast Cancer Res Treat. 2020;180:767–75. https://doi.org/10.1007/s10549-020-05576-8.CrossRefPubMed

55.

Chen H, Cantor A, Meyer J, Beth Corcoran M, Grendys E, Cavanaugh D, et al. Can older cancer patients tolerate chemotherapy?: A prospective pilot study. Cancer. 2003;97:1107–14. https://doi.org/10.1002/cncr.11110.CrossRefPubMed

56.

Kenis C, Decoster L, Bastin J, Bode H, Van Puyvelde K, De Grève J, et al. Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. J Geriatr Oncol. 2017;8:196–205. https://doi.org/10.1016/j.jgo.2017.02.010.CrossRefPubMed

57.

Demaria M, O’Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. Cancer Discov. 2017;7:165–76. https://doi.org/10.1158/2159-8290.CD-16-0241.CrossRefPubMed

58.

Sedrak MS, Gilmore NJ, Carroll JE, Muss HB, Cohen HJ, Dale W. Measuring Biologic Resilience in Older Cancer Survivors. J Clin Oncol. 2021;39:2079–89. https://doi.org/10.1200/JCO.21.00245.CrossRefPubMedPubMedCentral

59.

Shachar SS, Deal AM, Reeder-Hayes KE, Nyrop KA, Mitin N, Anders CK, et al. Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a. JNCI Cancer Spectrum. 2020;4:pkaa082. https://doi.org/10.1093/jncics/pkaa082.CrossRefPubMedPubMedCentral

60.

Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst. 2014;106:dju057. https://doi.org/10.1093/jnci/dju057.CrossRefPubMedPubMedCentral

61.

Sedrak MS, Cohen HJ. The Aging-Cancer Cycle: Mechanisms and Opportunities for Intervention. J Gerontol A Biol Sci Med Sci. 2022:glac247. https://doi.org/10.1093/gerona/glac247.

62.

Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, et al. Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. J Clin Oncol. 2023;41:295–306. https://doi.org/10.1200/JCO.22.00406.CrossRefPubMed

63.

van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, et al. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol. 2015;33:1918–27. https://doi.org/10.1200/JCO.2014.59.1081.CrossRefPubMed

64.

Witlox L, Hiensch AE, Velthuis MJ, Steins Bisschop CN, Los M, Erdkamp FLG, et al. Four-year effects of exercise on fatigue and physical activity in patients with cancer. BMC Med. 2018;16:86. https://doi.org/10.1186/s12916-018-1075-x.CrossRefPubMedPubMedCentral

65.

Lee K, Norris MK, Wang E, Dieli-Conwright CM. Effect of high-intensity interval training on patient-reported outcomes and physical function in women with breast cancer receiving anthracycline-based chemotherapy. Support Care Cancer. 2021;29:6863–70. https://doi.org/10.1007/s00520-021-06294-7.CrossRefPubMed

66.

Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study. Circulation. 2023;147:532–45. https://doi.org/10.1161/CIRCULATIONAHA.122.062814.CrossRefPubMed

67.

Artale S, Grillo N, Lepori S, Butti C, Bovio A, Barzaghi S, et al. A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer. Nutrients. 2022;14:1801. https://doi.org/10.3390/nu14091801.CrossRefPubMedPubMedCentral

68.

Nguyen LT, Dang AK, Duong PT, Phan HBT, Pham CTT, Nguyen ATL, et al. Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam. Cancer Med. 2021;10:1668–80. https://doi.org/10.1002/cam4.3766.CrossRefPubMedPubMedCentral

69.

Qin N, Jiang G, Zhang X, Sun D, Liu M. The Effect of Nutrition Intervention With Oral Nutritional Supplements on Ovarian Cancer Patients Undergoing Chemotherapy. Front Nutr. 2021;8: 685967. https://doi.org/10.3389/fnut.2021.685967.CrossRefPubMedPubMedCentral

70.

Chini C, Bascialla L, Giaquinto A, Magni E, Gobba SM, Proserpio I, et al. Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients. Support Care Cancer. 2021;29:917–23. https://doi.org/10.1007/s00520-020-05569-9.CrossRefPubMed

71.

Mooney KH, Beck SL, Wong B, Dunson W, Wujcik D, Whisenant M, et al. Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med. 2017;6:537–46. https://doi.org/10.1002/cam4.1002.CrossRefPubMedPubMedCentral

Title: Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study
Authors: Mina S. Sedrak
Can-Lan Sun
Marie Bae
Rachel A. Freedman
Allison Magnuson
Tracey O’Connor
Beverly Moy
Tanya M. Wildes
Heidi D. Klepin
Andrew E. Chapman
William P. Tew
Efrat Dotan
Mary Anne Fenton
Heeyoung Kim
Vani Katheria
Hyman B. Muss
Harvey J. Cohen
Cary P. Gross
Jingran Ji
Publication date: 28-04-2024
Publisher: Springer US
Published in: Journal of Cancer Survivorship
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-024-01594-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine